Skip to main content

Table 3 A: C-index analysis of with and without the addition of BSI to blood based biomarkers at baseline. B: C-index analysis of change in BSI and PSA at treatment follow-up

From: Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

 

C-index

Confidence interval

SE

A. Baseline analysisa (dead/total = 56/80)

   

 BSI

0.71

0.64–0.77

0.03

 PSA

0.65

0.57–0.72

0.03

 ALP

0.67

0.58–0.75

0.03

 HgB

0.26

0.20–0.32

0.03

 PSA + ALP + HgB

0.67

0.58–0.74

0.03

 PSA + ALP + HgB + BSI

0.72

0.64–0.78

0.03

B. Change (∆) at week 12 (dead/total = 40/62)

   

 ∆ BSI

0.75

0.68–0.81

0.05

 ∆ PSA

0.73

0.66–0.78

0.05

 ∆ PSA + ∆ BSI

0.77

0.71–0.82

0.05

  1. aBSI, PSA, ALP, and HgB values were observed skewed and therefore logarithmically transformed